Nordic Group BV
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nordic Group BV
The European Medicines Agency has recommended new uses for 11 approved medicines, including an antibody drug conjugate for treating advanced non-small cell lung cancer.
The European Medicines Agency has recommended that the therapeutic indications of Keytruda and Bavencio should be expanded again.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
The business unit is transitioning from being the clinical development arm of its parent company to a full-blown commercial operation in the U.S. and Europe.
- Hospitals, Nursing Homes, Institutions
- Large Molecule
- Other Names / Subsidiaries
- Nordic Drugs
- Nordic Pharma
- Disphar International
- Indeus Life Sciences
- Prague Clinical Services
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.